Today: 14 March 2026
Subscribe
Browse Category

NYSE:ABBV 25 January 2026 - 10 March 2026

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie shares closed up 1.8% at $231.50 Friday, outpacing Johnson & Johnson. U.S. markets will be closed Monday for Presidents Day, with trading set to resume Tuesday. Investors are weighing AbbVie’s drug-pricing moves and pipeline as the company shifts away from Humira after patent loss. Trading volume topped its recent average, with the stock about 5% below its 52-week high.
15 February 2026
··
AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie shares rose 0.7% to $224.83 Tuesday afternoon, near the session high, after BNP Paribas Exane raised its price target to $213 but kept a neutral rating. The stock traded in a narrow range as investors awaited delayed U.S. payrolls and inflation data for rate signals. U.S. stocks were mixed, with the Dow at a record high and S&P 500 little changed.
10 February 2026
··
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
7 February 2026
···
AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie shares climbed 2% to $223.45 in midday trading Friday after a volatile week. The move followed a quarterly report showing fourth-quarter net revenues up 10% to $16.62 billion and adjusted profit of $2.71 per share. Humira sales dropped 25.9% as biosimilar competition increased, while Skyrizi and Rinvoq posted gains. The company also announced new regulatory approvals and licensing deals.
6 February 2026
···
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie shares rose 0.7% to $219.02 in after-hours trading Thursday, rebounding after a nearly 6% drop following its earnings report. Skyrizi beat sales estimates with $5.01 billion, while Rinvoq missed at $2.37 billion. The company raised its 2026 forecast for the pair to $31.6 billion. Investors remain focused on whether new drugs can offset Humira’s ongoing decline.
6 February 2026
···
AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie shares fell 3.9% in after-hours trading Wednesday after quarterly results showed Rinvoq sales missed expectations at $2.37 billion. Skyrizi sales beat forecasts at $5.01 billion, while Humira revenue dropped 25.9% to $1.25 billion. The company projected 2026 adjusted earnings above estimates, but investors focused on challenges replacing Humira as biosimilar competition grows.
5 February 2026
···
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie shares fell 2.5% to $219.98 Wednesday after Rinvoq sales missed forecasts, despite the company raising its 2026 profit outlook. Q4 adjusted earnings reached $2.71 per share on $16.618 billion revenue; Skyrizi sales rose 32.5%, while Humira dropped 25.9%. AbbVie announced a three-year Medicaid pact with the Trump administration and pledged $100 billion in U.S. investments.
4 February 2026
···
AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie shares rose 0.8% to $227.55 Tuesday afternoon ahead of its quarterly earnings report due Wednesday morning. The company filed with U.S. and European regulators to expand Rinvoq’s use to non-segmental vitiligo, based on Phase 3 data. Investors are watching whether new immunology drugs can offset Humira’s sales decline.
3 February 2026
···
AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next

AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next

AbbVie shares closed Friday at $223.01, up 1.2%, outpacing big pharma peers as trading volume topped its 50-day average. The company reports earnings Wednesday, with analysts watching Skyrizi, Rinvoq, and the aesthetics segment. AbbVie’s full-year adjusted earnings guidance stands at $9.90 to $9.94. Investors remain cautious amid macroeconomic uncertainty and upcoming U.S. jobs data.
1 February 2026
··
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie shares closed up 0.7% at $220.77 on Monday, moving with broader Wall Street gains ahead of the Federal Reserve’s policy decision and major tech earnings. The company will report full-year and Q4 results before the market opens on Feb. 4. AbbVie recently signed a $650 million cancer drug licensing deal with RemeGen and faces investor scrutiny over its post-Humira growth strategy.
27 January 2026
···
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie shares rose 0.4% to $220.10 Monday, moving between $217.15 and $221.48 as investors awaited its Feb. 4 earnings report. Health-care stocks held firm, with the sector ETF up 0.4% and Johnson & Johnson and Pfizer also gaining. AbbVie’s upcoming results will highlight its immunology drugs as it faces pressure from declining Humira sales and recent policy deals. Traders are watching Wednesday’s Fed decision before the earnings release.
26 January 2026
···
AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
1 2 3 … 5

Stock Market Today

  • Arm Holdings Share Price Valuation: Overvalued Amid Semiconductor Sector Focus
    March 14, 2026, 1:39 AM EDT. Arm Holdings' stock has shown mixed short-term returns, including a 7.6% decline over 30 days and a modest year-to-date gain of 0.9%. The company, key in semiconductor chip design, scores poorly on valuation checks, with a rating of 1 out of 6 by Simply Wall St. A discounted cash flow (DCF) analysis estimates Arm's intrinsic value at $51.70 per share, implying it is overvalued by 123.9% relative to current prices. The price-to-sales ratio stands at 26.32 times, significantly above the semiconductor industry average of 5.58, reflecting high growth expectations but increased risk. This suggests that Arm's current market price may not fully align with traditional valuation models, prompting investors to reassess its long-term pricing and potential.
Go toTop